• Home
  • About GCCA
  • Videos & Speakers
    • Presentations: Part 1
    • Presentations: Part 2
    • Speakers
  • Sponsors
  • TOOLKIT
  • Past Events
  • Contact Us
  • More
    • Home
    • About GCCA
    • Videos & Speakers
      • Presentations: Part 1
      • Presentations: Part 2
      • Speakers
    • Sponsors
    • TOOLKIT
    • Past Events
    • Contact Us

  • Home
  • About GCCA
  • Videos & Speakers
  • Sponsors
  • TOOLKIT
  • Past Events
  • Contact Us

PRESENTATIONS: PART 2

Part 2 Opening Remarks

A brief overview of what you can expect from part 2 of the 2022 Global Colorectal Cancer Congress from GCCA President, Nicole Sheahan.

Enlighten Roundtable

Global CRC patient-centered policy roundtable discussion on establishing an advocacy roadmap for organizations and patient advocates to effect change.  

Interview with Dr. Luc Colemont

President and Managing Director of Stop Darmkanker discusses developing eye-catching campaigns and provides valuable social media tips to engage your audience.

Universal DPD/DPYD Testing

This session discusses the importance of genetic testing for DPD deficiency prior to chemotherapy with Fluorouracil (5-FU) or Capecitabine (Xeloda). 

Understanding Biologics and Biosimilars An Overview

An overview of biologics and biosimilar medicines.  Our expert speakers share how advocates can bring the patient voice to biosimilar policies around the world. For more information on biosimilars, check out GCCA's Biosimilars Training Program.

Best Practices For Working With Industry

Best practices and communication strategies for patient advocacy organizations to help build relationships, navigate sponsorships, and programming support from the biopharmaceutical industry.

Program Closing Remarks

A brief wrap-up of the 2 part event.

Copyright © 2022 GCCA Congress 2022 - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept